NICE Proposes To Refuse Nexavar(R) (Sorafenib) For Liver Cancer Patients

Today, in an alarming move, the National Institute for Health and Clinical Excellence (NICE) has, once again, proposed to deny Nexavar® (sorafenib) for the treatment of advanced hepatocellular carcinoma (HCC) - a form of liver cancer. Nexavar® is the only systemic treatment option that could potentially extend the survival of these patients.